Edition:
United States

Oramed Pharmaceuticals Inc (ORMP.OQ)

ORMP.OQ on NASDAQ Stock Exchange Capital Market

3.25USD
15 Feb 2019
Change (% chg)

$-0.06 (-1.81%)
Prev Close
$3.31
Open
$3.29
Day's High
$3.32
Day's Low
$3.24
Volume
6,824
Avg. Vol
11,797
52-wk High
$8.50
52-wk Low
$2.79

Latest Key Developments (Source: Significant Developments)

Oramed Receives Additional $3 Million Milestone Payment From HTIT
Wednesday, 9 Jan 2019 08:40am EST 

Jan 9 (Reuters) - Oramed Pharmaceuticals Inc ::ORAMED RECEIVES ADDITIONAL $3 MILLION MILESTONE PAYMENT FROM HTIT.  Full Article

Oramed Granted Japanese Patent For GLP-1 Analog Capsule
Tuesday, 24 Jul 2018 08:25am EDT 

July 24 (Reuters) - Oramed Pharmaceuticals Inc ::ORAMED GRANTED JAPANESE PATENT FOR GLP-1 ANALOG CAPSULE.  Full Article

Oramed Announces $18.1 Mln Registered Direct Offering
Tuesday, 3 Jul 2018 01:48am EDT 

July 3 (Reuters) - Oramed Pharmaceuticals Inc ::ORAMED ANNOUNCES $18.1 MILLION REGISTERED DIRECT OFFERING.ENTERED INTO DEFINITIVE AGREEMENTS WITH SEVERAL HEALTHCARE-FOCUSED INSTITUTIONAL INVESTORS.ORAMED PHARMACEUTICALS- AGREEMENTS FOR BUY 2.9 MILLION SHARES OF ITS STOCK AND WARRANTS TO PURCHASE UP TO 2.9 MILLION SHARES OF ITS COMMON STOCK.REGISTERED DIRECT OFFERING AT A COMBINED PURCHASE PRICE OF $6.25 PER SHARE AND RELATED WARRANTS.  Full Article

Oramed receives approval for clinical study to treat NASH
Tuesday, 14 Nov 2017 08:00am EST 

Nov 14 (Reuters) - Oramed Pharmaceuticals Inc :Oramed receives regulatory approval to conduct clinical study for treatment of NASH with its oral insulin capsule.Israel's ministry of health granted company approval to initiate exploratory clinical study of ORMD-0801 in patients with NASH​.Proposed study will assess effectiveness of ORMD-0801 in reducing liver fat content, inflammation and fibrosis in patients with NASH​.Says ‍plans on initiating study in coming month​.  Full Article